RxDoctor Payments Data

Bruce Brown, MD

Cardiovascular Disease · Wareham, MANPI 1205896362

Payments from drug & device makers

$6,784in general payments, 2019–2025

Across 348 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Amgen$693
  • Alnylam Pharmaceuticals Inc.$609
  • Boston Scientific$520
  • E.r. Squibb & Sons, L.L.C.$407
  • Boehringer Ingelheim$304
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$6,72499%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,784 in reported general payments places this provider in the 65th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$248,764
Medicare patients
993
Services billed
3,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban357$445,958
XareltoRivaroxaban98$141,685
EntrestoSacubitril/Valsartan66$113,364
JardianceEmpagliflozin39$58,552
Repatha SureclickEvolocumab19$28,341
Repatha SyringeEvolocumab12$18,930
Praluent PenAlirocumab16$17,711
FarxigaDapagliflozin Propanediol16$11,123
Ranolazine ErRanolazine59$8,512
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,389
Metoprolol Succinate411$7,394
Diltiazem 24hr Er (Cd)Diltiazem Hcl155$6,592
Atorvastatin Calcium339$4,881
Rosuvastatin Calcium102$3,675
Amlodipine Besylate304$2,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$216$445,958357 claims
Johnson & JohnsonXarelto$1,994$141,68598 claims
NovartisEntresto$298$113,36466 claims
Boehringer IngelheimJardiance$304$58,55239 claims
AstraZenecaFarxiga$230$11,12316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Wareham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →